SK76699A3 - Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments - Google Patents

Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments Download PDF

Info

Publication number
SK76699A3
SK76699A3 SK766-99A SK76699A SK76699A3 SK 76699 A3 SK76699 A3 SK 76699A3 SK 76699 A SK76699 A SK 76699A SK 76699 A3 SK76699 A3 SK 76699A3
Authority
SK
Slovakia
Prior art keywords
formula
methyl
pyrrolo
methylpropyl
naphthalenylmethyl
Prior art date
Application number
SK766-99A
Other languages
English (en)
Slovak (sk)
Inventor
Martin Cooper
David Cheshire
David Donald
Mark Furber
Matthew Perry
Richard Harrison
Nicholas Tomkinson
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of SK76699A3 publication Critical patent/SK76699A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK766-99A 1996-12-21 1997-12-18 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments SK76699A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9626643.2A GB9626643D0 (en) 1996-12-21 1996-12-21 Compounds
PCT/SE1997/002157 WO1998028301A1 (en) 1996-12-21 1997-12-18 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments

Publications (1)

Publication Number Publication Date
SK76699A3 true SK76699A3 (en) 2000-05-16

Family

ID=10804862

Family Applications (1)

Application Number Title Priority Date Filing Date
SK766-99A SK76699A3 (en) 1996-12-21 1997-12-18 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments

Country Status (23)

Country Link
US (8) US6046204A (cg-RX-API-DMAC10.html)
EP (1) EP0946562B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001507687A (cg-RX-API-DMAC10.html)
KR (1) KR20000069605A (cg-RX-API-DMAC10.html)
CN (1) CN1246119A (cg-RX-API-DMAC10.html)
AT (1) ATE215088T1 (cg-RX-API-DMAC10.html)
AU (1) AU717429B2 (cg-RX-API-DMAC10.html)
BR (1) BR9714063A (cg-RX-API-DMAC10.html)
CA (1) CA2275312A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ289925B6 (cg-RX-API-DMAC10.html)
DE (1) DE69711430T2 (cg-RX-API-DMAC10.html)
EE (1) EE9900315A (cg-RX-API-DMAC10.html)
GB (1) GB9626643D0 (cg-RX-API-DMAC10.html)
HU (1) HUP0002839A3 (cg-RX-API-DMAC10.html)
ID (1) ID21682A (cg-RX-API-DMAC10.html)
IL (1) IL130538A0 (cg-RX-API-DMAC10.html)
IS (1) IS5082A (cg-RX-API-DMAC10.html)
NO (1) NO993027L (cg-RX-API-DMAC10.html)
NZ (1) NZ336124A (cg-RX-API-DMAC10.html)
PL (1) PL334228A1 (cg-RX-API-DMAC10.html)
SK (1) SK76699A3 (cg-RX-API-DMAC10.html)
TR (1) TR199901433T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998028301A1 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
AU2107700A (en) 1999-01-15 2000-08-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides with pde-iv inhibiting activity
EP1147103B1 (en) 1999-01-15 2005-05-04 ALTANA Pharma AG Phenantrhridine-n-oxides with pde-iv inhibiting activity
ATE356810T1 (de) 1999-01-15 2007-04-15 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
US6361486B1 (en) * 2000-02-29 2002-03-26 Agilent Technologies, Inc. Coaxial-drive centrifuge providing tilt control relative to centrifugal force
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US7589202B2 (en) * 2000-08-14 2009-09-15 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
TW200407315A (en) * 2002-04-23 2004-05-16 Sankyo Co Pyrimidine derivatives
CA2533534C (en) * 2003-07-24 2013-03-19 Tecomet, Inc. Assembled non-random foams
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
DK2024367T3 (da) 2006-05-04 2011-01-03 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
WO2009100403A1 (en) * 2008-02-07 2009-08-13 Neurogen Corporation Substituted aryl pyrimidinones
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2464354B1 (en) 2009-08-10 2015-04-01 The Regents of The University of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
USRE48842E1 (en) 2011-05-27 2021-12-07 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CN108129486B (zh) * 2018-01-25 2020-06-05 华东理工大学 嘧啶酮衍生物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
GB9424842D0 (en) * 1994-12-09 1995-02-08 British Tech Group Pharmaceutical compositions

Also Published As

Publication number Publication date
PL334228A1 (en) 2000-02-14
US6136974A (en) 2000-10-24
AU717429B2 (en) 2000-03-23
US6211368B1 (en) 2001-04-03
CN1246119A (zh) 2000-03-01
GB9626643D0 (en) 1997-02-12
CA2275312A1 (en) 1998-07-02
AU5580998A (en) 1998-07-17
US6306863B1 (en) 2001-10-23
EP0946562A1 (en) 1999-10-06
US6046204A (en) 2000-04-04
ATE215088T1 (de) 2002-04-15
BR9714063A (pt) 2002-01-02
TR199901433T2 (xx) 1999-09-21
CZ289925B6 (cs) 2002-04-17
NZ336124A (en) 2001-03-30
ID21682A (id) 1999-07-08
NO993027D0 (no) 1999-06-18
IL130538A0 (en) 2000-06-01
JP2001507687A (ja) 2001-06-12
KR20000069605A (ko) 2000-11-25
EP0946562B1 (en) 2002-03-27
US6166206A (en) 2000-12-26
DE69711430T2 (de) 2002-10-31
US20030162798A1 (en) 2003-08-28
US20020025966A1 (en) 2002-02-28
EE9900315A (et) 2000-02-15
IS5082A (is) 1999-06-14
DE69711430D1 (de) 2002-05-02
HUP0002839A2 (hu) 2001-02-28
CZ220499A3 (cs) 2000-02-16
WO1998028301A1 (en) 1998-07-02
HUP0002839A3 (en) 2001-04-28
NO993027L (no) 1999-08-20
US6229013B1 (en) 2001-05-08

Similar Documents

Publication Publication Date Title
US6306863B1 (en) Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
CA2150709C (en) Pyrazolopyrimidines
EP3983064B1 (en) Cot modulators and methods of use thereof
US20050032808A1 (en) 5 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
SK151399A3 (en) Thieno[2,3-d]pyrimidine diones, preparation method thereof, pharmaceutical compositions containing the same and their use
KR20010006350A (ko) 신규 화합물
CZ20021743A3 (cs) Bicyklické dusíkové heterocykly substituované alkylaminoskupinou jako inhibitory P38 proteinkinázy
WO1995028387A1 (en) Benzamide compound and medicinal use thereof
US9260448B2 (en) Thienopyrimidinone derivatives as mGluR1 antagonists
SK118798A3 (en) Pharmaceutically useful compounds
Bibi et al. Exploring the ability of dihydropyrimidine-5-carboxamide and 5-benzyl-2, 4-diaminopyrimidine-based analogues for the selective inhibition of L. major Dihydrofolate reductase
KR19980039641A (ko) 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
CZ195293A3 (en) PROCESS FOR PREPARING IN 5-POSITION SUBSTITUTED PYRROLO(2,3-d) PYRIMIDINES
CA1293727C (en) 9-deazaguanines
CA3153115A1 (en) Thienopyrimidones as trpa1 inhibitors
US6472425B1 (en) Methods for treating female sexual dysfunctions
JP4109890B2 (ja) 医薬組成物
US5281708A (en) 9-Substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors of PNP
WO1998054185A1 (en) 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-ones
MXPA99005779A (en) Pyrrolo[3,4-d
KR100377788B1 (ko) 신규한 피리도피리미딘 유도체, 그 제조방법 및 이를포함하는 약제학적 조성물
KR100479019B1 (ko) 캐테콜히드라존유도체,이의제조방법및그를함유한약제학적조성물
HK40071835A (en) Cot modulators and methods of use thereof
HK40071835B (en) Cot modulators and methods of use thereof
JPH06239840A (ja) ピリミジン環縮合シクロペンチリデン誘導体